It will offer people who are immunosuppressed or immunocompromised a Pfizer, Moderna or Novavax vaccine to determine whether this will give a stronger immune response than two doses.
The trial has published preliminary data showing that 89 per cent of people who are immunocompromised or immunosuppressed generate antibodies following vaccination, and 60 per cent generated a strong antibody response following two doses of a vaccine.
The government’s said:
“We know some people may get less protection from the vaccine than others, so we are planning for a booster programme in the autumn, prioritising those most at risk. This new study will play an important role in helping to shape the deployment of future vaccines doses for these specific at-risk groups.”